Adult Rhabdomyosarcoma: Clinical Features and Radiotherapy Outcomes—The Turkish Oncology Group (TOG) Bone and Soft Tissue Sarcoma Study Group

The follow-uptime was from 3 to 235 (median 18) months, disease-free survival was between 2 and 48 (median 12)months, and 5-year overall survival (OS) was 25% (median OS 20 (4–235) months).

📌 3 Key Takeaways

🎯

Objective & Hypothesis:OBJECTIVEAlthough rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma diagnosed in childhood,it represents only 2%–5% of adult soft tissue sarcomas.

📊

Key Findings & Data:The aim of the present study was to better understand the clinical characteristics, treatment approaches, and outcomes of patients with adult RMS whoreceived radiotherapy (RT) as a component of their multidisciplinary management since there are scarcedata on adult RMS due to its rarity.METHODSThe medical records of patients with adult RMS who were ≥18 years old and treated with RT betweenJanuary 1995 and August 2016 in four different radiation centers were evaluated in terms of clinicalcharacteristics, treatment, and follow-up data retrospectively.RESULTSThere were 28 patients.

💡

Conclusion & Impact:The follow-uptime was from 3 to 235 (median 18) months, disease-free survival was between 2 and 48 (median 12)months, and 5-year overall survival (OS) was 25% (median OS 20 (4–235) months).

🔬Design:Research Article

📍Scope:2016 Verileri

⚙️Variables:Domain Parameters

Abstract

OBJECTIVEAlthough rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma diagnosed in childhood,it represents only 2%–5% of adult soft tissue sarcomas. The aim of the present study was to better understand the clinical characteristics, treatment approaches, and outcomes of patients with adult RMS whoreceived radiotherapy (RT) as a component of their multidisciplinary management since there are scarcedata on adult RMS due to its rarity.METHODSThe medical records of patients with adult RMS who were ≥18 years old and treated with RT betweenJanuary 1995 and August 2016 in four different radiation centers were evaluated in terms of clinicalcharacteristics, treatment, and follow-up data retrospectively.RESULTSThere were 28 patients. The median age at diagnosis was 28 (19–53) years. The most common site of involvement was the head and neck (25%), and parameningeal region involvement was prominent (92%)among them. In general, unfavorable site of involvement was markedly higher than favorable ones (82%vs. 18%). Alveolar and pleomorphic subtypes compromised 75% of the cases. Fifteen patients had surgery, 26 chemotherapy, 10 radical intent of RT, 9 adjuvant, 3 preoperative, and 6 palliative. The follow-uptime was from 3 to 235 (median 18) months, disease-free survival was between 2 and 48 (median 12)months, and 5-year overall survival (OS) was 25% (median OS 20 (4–235) months). There were significant differences in terms of survival according to histopathological subtypes (p: 0.017), risk groups(p

🔖

Cite This Article

KAMER, S., DARENDELILER, E., ANACAK, Y., ATALAR, B., AĞAOĞLU, F., İRIBAŞ, A., KIRAKLI, E. K., ERGEN, A., DINÇBAŞ, F. Ö. (2022). Adult Rhabdomyosarcoma: Clinical Features and Radiotherapy Outcomes—The Turkish Oncology Group (TOG) Bone and Soft Tissue Sarcoma Study Group. Türk Onkoloji Dergisi, Cilt: 33 - Sayı: 4, 129–135. https://ajindex.com/articles/639250

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (9)

Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) SoftTissue SarcomaCommittee experience and rationale for current COG studies. Pediatr Blood Cancer 2012;59(1):5–10
Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a singleinstitution. Cancer 2003;98(3):571–80
Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61(2):209–20
Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71(5):1904–22
Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13(3):610–30
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19(12):3091–102
Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma 2001;5(1):9–15
Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19(5):1238–47
Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer 2002;95(2):377–88. 10.Spalteholz M, Gulow J. Pleomorphic rhabdomyosarcoma infiltrating thoracic spine in a 59-year-old female patient: Case report. GMS Interdiscip Plast Reconstr Surg DGPW 2017;6:Doc11. 11.Khosla D, Sapkota S, Kapoor R, Kumar R, Sharma SC. Adult rhabdomyosarcoma: Clinical presentation, treatment, and outcome. J Cancer Res Ther 2015;11(4):830–4. 12.Van Gaal JC, De Bont ES, Kaal SE, Versleijen-Jonkers Y, van der Graaf WT. Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: the road ahead. Crit Rev Oncol Hematol 2012;82(3):259–79. 13.Leonard L. Gunderson, editors. Pediatric Soft Tissue Sarcomas. In: Clinical Radiation Oncology. 4th ed. Philadelphia: Elseiver: 2016. p.1408. 14.Enneking W, editor. Stagin